Originally published as JCO Early Release 10.1200/JCO.2005.02.9975 on February 6 2006

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wong, J. S. Articles by Smith, B. L. Search for Related Content PubMed PubMed Citation Articles by Wong, J. S. Articles by Smith, B. L. Related Articles Related Editorial

Prospective Study of Wide Excision Alone for Ductal Carcinoma in Situ of the Breast

From the Departments of Radiation Oncology, Surgery, Pathology, and Biostatistics and Computational Biology, Dana-Farber/Brigham and Women's Cancer Center; Departments of Surgery and Pathology, Massachusetts General Hospital; and Departments of Surgery and Pathology, Beth Israel Deaconess Medical Center; Harvard Medical School, Boston, MA

Address reprint requests to Julia Wong, MD, Department of Radiation Oncology, Dana-Farber Cancer Institute, 44 Binney St, L2, Boston, MA 02115; e-mail: jwong{at}lroc.harvard.edu

PURPOSE: It has been hypothesized that wide excision alone with margins 1 cm may be adequate treatment for small, grade 1 or 2 ductal carcinoma in situ (DCIS). To test this hypothesis, we conducted a prospective, single-arm trial.

METHODS: Entry criteria included DCIS of predominant grade 1 or 2 with a mammographic extent of 2.5 cm treated with wide excision with final margins of 1 cm or a re-excision without residual DCIS. Tamoxifen was not permitted. The accrual goal was 200 patients.

RESULTS: In July 2002, the study closed to accrual at 158 patients because the number of local recurrences met the predetermined stopping rules. The median age was 51 and the median follow-up time was 40 months. Thirteen patients developed local recurrence as the first site of treatment failure 7 to 63 months after study entry. The rate of ipsilateral local recurrence as first site of treatment failure was 2.4% per patient-year, corresponding to a 5-year rate of 12%. Nine patients (69%) experienced recurrence of DCIS and four (31%) experienced recurrence with invasive disease. Twelve recurrences were detected mammographically and one was palpable. Ten were in the same quadrant as the initial DCIS and three were elsewhere within the ipsilateral breast. No patient had positive axillary nodes at recurrence or subsequent metastatic disease.

CONCLUSION: Despite margins of 1 cm, the local recurrence rate is substantial when patients with small, grade 1 or 2 DCIS are treated with wide excision alone. This risk should be considered in assessing the possible use of radiation therapy with or without tamoxifen in these patients.

Presented in part at the 26th Annual San Antonio Breast Cancer Symposium, December 3-6, 2003, San Antonio, TX.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Related Editorial

• Is Excision Alone Adequate Treatment for Low-Risk Ductal Carcinoma-in-Situ of the Breast?
  Lawrence J. Solin
  JCO 2006 24: 1017-1019 [Full Text]

This article has been cited by other articles:

				A. Vincent-Salomon, C. Lucchesi, N. Gruel, V. Raynal, G. Pierron, R. Goudefroye, F. Reyal, F. Radvanyi, R. Salmon, J.-P. Thiery, et al. Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast Clin. Cancer Res., April 1, 2008; 14(7): 1956 - 1965. [Abstract] [Full Text] [PDF]

				P. Meijnen, H. S. A. Oldenburg, J. L. Peterse, H. Bartelink, and E. J. Th. Rutgers Clinical Outcome after Selective Treatment of Patients Diagnosed with Ductal Carcinoma In Situ of the Breast Ann. Surg. Oncol., January 1, 2008; 15(1): 235 - 243. [Abstract] [Full Text] [PDF]

				E. S. Hwang, D. L. Miglioretti, R. Ballard-Barbash, D. L. Weaver, K. Kerlikowske, and for the National Cancer Institute Breast Cancer Su Association between Breast Density and Subsequent Breast Cancer Following Treatment for Ductal Carcinoma In situ Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2587 - 2593. [Abstract] [Full Text] [PDF]

				J. C. Boughey, R. J. Gonzalez, E. Bonner, and H. M. Kuerer Current Treatment and Clinical Trial Developments for Ductal Carcinoma In Situ of the Breast Oncologist, November 1, 2007; 12(11): 1276 - 1287. [Abstract] [Full Text] [PDF]

				A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, H. -J. Senn, and Panel Members Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann. Onc., July 1, 2007; 18(7): 1133 - 1144. [Abstract] [Full Text] [PDF]

				P. Meijnen, N. Bijker, H. Bartelink, and E. J. Th. Rutgers In Reply J. Clin. Oncol., February 1, 2007; 25(4): 462 - 462. [Full Text] [PDF]

				J. S. Wong, S. C. Lester, and B. L. Smith In Reply: J. Clin. Oncol., August 10, 2006; 24(23): 3811 - 3812. [Full Text] [PDF]

				N. Bijker, P. Meijnen, J. L. Peterse, J. Bogaerts, I. Van Hoorebeeck, J.-P. Julien, M. Gennaro, P. Rouanet, A. Avril, I. S. Fentiman, et al. Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853--A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group J. Clin. Oncol., July 20, 2006; 24(21): 3381 - 3387. [Abstract] [Full Text] [PDF]

				L. J. Solin Is Excision Alone Adequate Treatment for Low-Risk Ductal Carcinoma-in-Situ of the Breast? J. Clin. Oncol., March 1, 2006; 24(7): 1017 - 1019. [Full Text] [PDF]